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Plasma levels of tumour necrosis factor and its soluble
receptors correlate with clinical features and outcome
of Hodgkin's disease patients
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Summary A prospective study was performed to assess the use of plasma measurement of tumour necrosis factor (TNF), lymphotoxin alpha
(LTax) and their soluble receptors (p55 and p75) for prognostic risk assignment in 61 patients with Hodgkin's disease. Plasma levels of TNF,
p55 and p75, but not of LTax, were higher in Hodgkin's disease patients than in healthy controls. Plasma levels of TNF, p55 and p75 were
associated with several prognostic factors for Hodgkin's disease, including those related to the host (age, performance status) and to the
tumour (disease stage, extranodal site involvement, bulky tumour, serum levels of LDH and ,B2-microglobulin, histology). Elevated plasma
levels of TNF, p55 and p75 were also associated with several parameters reflecting an immune activation, including the presence of B
symptoms, elevated serum levels of gammaglobulins, alkaline phosphatase and fibrinogen, as well as peripheral monocytosis, anaemia and
low serum albumin levels. Finally, elevated TNF ligand receptor plasma markers were associated with a lower incidence of complete
response to therapy and predicted shorter free-from-progression survival and overall survival of the patients. These results indicate that the
plasma levels of TNF and its soluble receptors correlate with clinical features and outcome of patients with Hodgkin's disease.
Keywords: tumour recrosis factor; ligand; receptor; Hodgkin's disease; prognosis
An important issue in Hodgkin's disease (HD) is the identification
ofprognostic factors that influence response to therapy and outcome
ofthe patients. The most common factors that have been found to be
associated with an unfavourable outcome include advanced stage,
presence of extranodal disease and bulky tumour, mixed cellularity
or lymphocyte depletion histology, age above 45 years, presence of
B symptoms, male gender, elevated serum levels of LDH, P2-
microglobulin, alkaline phosphatase and low serum albumin levels.
However, despite the presence ofseveral prognostic indices for HD,
there is no agreement on the definition of sufficiently high-risk
groups ofpatients for whom the prognosis is especially poor and for
whom up-front high-dose therapy should be advised (Wagstaffet al,
1988; Straus et al, 1990; Proctoret al, 1991; Hasencleveret al, 1995;
Lee et al, 1997). Thus, the search for more discriminating prognostic
factors identifying vulnerable patients with a high risk of resistance
or relapse is still an open challenge.
Hodgkin's disease is frequently accompanied by systemic symp-
toms, increased erythrocyte sedimentation rate, hyperfibrinogen-
aemia, thrombocytosis, anaemia and eosinophilia. Histologically,
HD is characterized by the presence ofalow proportion ofHodgkin's
and Reed-Steinberg (H-RS) cells, with a predominant reactive
lymphocyte population and mixed degrees of fibrosis or sclerosis
within surrounding lymphoid tissue. Populations of H-RS cells and
reactive cells are both capable of producing a panel of different
cytokines and receptors (Gruss and Dower, 1995). It seems probable
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therefore that the majorclinical and histopathological features ofHD
reflect the production of cytokines by either the neoplastic or the
reactive cell populations.
Tumour necrosis factor (TNF) was originally identified as
cachectin, a soluble factor involved in weight loss, fever and
anaemia, but it was soon demonstrated that TNF is a central medi-
ator ofinflammatory processes, generating a cytokine cascade that
includes the production of interleukin 1, interleukin 6 and other
secreted proteins, as well as TNF itself (Warzocha et al, 1995;
Bazzoni and Beutler, 1996). In addition, TNF and LToc (formerly
known as TNF-f) have been recently identified to participate in
the development and in the function of normal lymphoid tissues
(Le Hir et al, 1996; Pasparakis et al, 1996). Two receptors, p55
(TNF-RI) and p75 (TNFR-II), mediate the effects ofTNF and LTc(
on target cells through several pathways leading to cell activation,
proliferation or apoptotic death. Soluble forms of both receptors
have been identified in biological fluids and modulate the effects
of the cytokines (Warzocha et al, 1995; Bazzoni and Beutler,
1996). The observation of structural similarities between several
molecules and TNF or its receptors has resulted in the definition of
a larger family of molecules, including TNF, LTx, LT,B, Fas and
the antigens CD40, CD30 and CD27, many of these molecules
being involved in the immune system regulation.
Stimulation ofthe CD30 antigen, a memberofthe TNF receptor
family, regarded as being a peculiar attribute of H-RS cells,
resulted in inducible secretion ofboth TNF and LTox by these cells
(Gruss et al, 1995). Furthermore, H-RS cells express several TNF
receptors, including those specific for TNF and LTct (Gruss and
Dower, 1995). In addition, it is of interest that both cytokines and
the soluble forms of their receptors were found to be elevated in
patients with non-Hodgkin's lymphoma (NHL) and that TNF, p55
and p75 plasma levels represented valuable prognostic markers in
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those individuals (Salles et al, 1996; Warzocha et al, 1997). In the
current prospective study, we demonstrated that elevated plasma
levels ofTNF and its soluble receptors were present in a subset of
HD patients who had several adverse prognostic factors at the time
ofdiagnosis. In addition, elevated levels strongly predicted shorter
free-from-progression (FFP) survival and overall survival of the
patients. These data suggest the possible use of TNF and its
soluble receptors as serum markers for risk assignment in HD.
METHODS
Patients
From October 1991 to November 1996, 61 recently diagnosed HD
patients (23 women and 38 men) were consecutively admitted to
our department and enrolled in this study. The median patient age
was 37 years (range 15-75). Patients with active bacterial or
fungal infection and those who tested positive for the human
immunodeficiency virus were excluded from the study. Patients
with a previous history of autoimmune disease as well as patients
who had received steroid therapy were also excluded from the
analysis. In all patients, the diagnosis was based on lymph node
histology, with the lymphocyte predominance subtype being found
in three patients, nodular sclerosis in 38, mixed cellularity in 16
and lymphocyte depletion in four patients. The initial medical
evaluation consisted of complete history and physical examina-
tion, radiographic examination of the chest, computerized
tomographic scan of the chest, abdomen and pelvis, and blood
chemistry. The extent of disease and the presence of B symptoms
were categorized according to the Ann Arbor staging classifica-
tion. Bulky disease was defined by a mass greater than 10 cm in its
largest dimension or by a mediastinal mass greater than one-third
of the maximal thoracic diameter on a standing chest radiograph.
Clinical characteristics ofthepatients included in the present study
are shown in Table 1.
Treatment
Treatment was defined according to the initial HD stage. Among
these 61 patients, five underwent radiotherapy alone, 41 were
treated with chemotherapy and radiotherapy, and 15 patients
received only chemotherapy. Chemotherapy regimens consisting
of MOPP-ABVD alternated, MOPP/ABV-hybrid and ABVD-like
protocols were used, respectively, in 17, 9 and 30 patients. A
complete response to treatment was defined as the disappearance
of all clinical manifestations of the disease and normalization of
all laboratory values. Free-from-progression survival was calcu-
lated from the date of treatment initiation until relapse, disease
progression or the last follow-up evaluation. Overall survival was
measured as the time between the beginning of treatment and
death or the date ofthe last follow-up evaluation.
Evaluation of plasma cytokine and receptor levels
All samples were collected before treatment initiation using sterile
tubes containing EDTA to prevent furtherrelease ofcytokines before
analysis. Plasma samples were tested using ELISA kits for TNF
(Medgenix Diagnostics, Fleurus, Belgium), LTax (R&D Systems,
Minneapolis, MN, USA), p55 and p75 (Roche, Basle, Switzerland).
The detection limits ofthe ELISA tests used were 3 pg ml-' forTNF,
7 pg ml-' for LToc, 0.1 ng ml-' for p55 and 1 ng ml-' for p75. Plasma
Table 1 Characteristics of patients with Hodgkin's disease and association
of the TNF, p55 and p75 plasma levels (mean values) with clinical features of
the disease
Characteristics Number of TNF p55 p75
patients
Age
60 years
> 60 years
Performance status (ECOG)
<2
2
Weight loss
Absent
Present
Fever
Absent
Present
Sweats
Absent
Present
Serum albumin
2 35 g I-
< 35 g 1-'
Haemoglobin
2 12 g dl-1
< 12gdl-1
Ann Arbor stage
1,11
IlIl, IV
Serum LDH
2 1 x Normal
> 1 x Normal
Serum 2-microglobulin
2 3.0 mg 1-'
> 3.0 mg 1-'
Bulky tumour (10cm)
Absent
Present
Extranodal involvement
Bone marrow
Absent
Present
Spleen
Absent
Present
Liver
Absent
Present
Pleura
Absent
Present
Histology
Lymphocyte predominance
Nodular sclerosis
Mixed cellularity
Lymphocyte depletion
<0.02
55 32.2
6 66.3
<0.0005
53 30.1
8 71.5
<0.0001
50 28.3
11 68.6
<0.0001
39 23.1
22 57.6
<0.01
47 29.9
14 54.4
<0.0001
49 26.7
12 71.8
<0.001
37 24.7
24 52.3
<0.0001
39 23.9
22 56.2
<0.05
48 31.1
13 52.1
<0.0001
53 27.1
8 91.3
<0.0005
54 30.5
7 74.1
<0.005
57 32.4
4 80.0
<0.0001
51 27.8
10 74.8
<0.05
55 33.1
6 58.3
<0.05
56 32.8
5 66.0
3
38
16
4
<0.0001
2.9
6.0
<0.0001
2.8
5.4
<0.0001
2.8
5.1
<0.0005
2.5
4.3
<0.001
2.8
4.5
<0.0001
2.7
5.3
<0.001
2.6
4.1
<0.05
2.8
3.9
NS
3.0
4.0
<0.0001
2.8
5.7
<0.005
2.9
5.1
<0.0001
2.9
6.9
<0.0005
2.8
5.1
<0.05
3.0
4.5
<0.05
3.0
4.9
13.3 2.5
28.3 2.9
49.3 4.0
66.0 3.1
<0.005
5.1
12.3
<0.0005
4.9
12.2
<0.0001
4.4
12.2
<0.0005
3.9
9.2
<0.005
4.7
9.6
<0.0001
4.3
12.0
<0.005
4.2
8.4
<0.005
4.2
8.7
<0.01
4.8
9.5
<0.0001
4.9
15.4
NS
5.6
7.8
<0.0001
5.1
16.7
<0.0001
4.7
13.3
<0.0005
5.0
13.4
<0.005
5.2
12.6
3.2
4.4
9.8
6.1
Student's t-test P-value in bold; NS denotes non-significant.
samples from 20 healthy subjects, including five women and 15 men,
with a median age of 30 years (range 22-50), served as controls for
the detection ofthese proteins.
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Statistical analyses
Comparison of the cytokine and receptor plasma values between
the patients and healthy controls, and all differences in means were
tested using the paired Student's t-test. Linear correlations were
determined using the Pearson test. Univariate analysis was
performed using Yates corrected X2 test. The FFP survival and
overall survival were estimated using the Kaplan-Meier method,
and statistical differences were assessed using the log-rank test.
Statistical analysis was performed using the Statistica software
(Statsoft, Tulsa, OK, USA).
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RESULTS
Plasma cytokine and receptor levels
TNF, LToc, p55 and p75 were detectable in all patients' plasma
samples collected at diagnosis before treatment. Their mean values
were not statistically different in men compared with women. TNF
mean plasma values were higher in HD patients (mean 35.5 pg ml-',
range 9-142 pg ml-') than in healthy controls (mean 11 pg ml-',
range 5-14 pg ml-') (P < 0.0001). LToc mean plasma values were
10.5 pg ml' (range 7.0-18.8 pg ml-') in patients, and this was not
statistically different from the healthy controls' values (mean
9.5 pg ml', range 7.0-12.5 pg ml-'). Soluble p55 receptor plasma
levels obtained in the patients ranged from 1.2 ng ml' to 11.5 ng ml-'
(mean 3.2 ng ml-'), whereas, in 20 healthy controls, values ranged
from l.5ng ml' to 3.4ng ml-' (mean 2.3ng ml-') (P<0.0001).
Soluble p75 receptor plasma levels ranged from 2.2 ng ml-' to
38.4 ng ml' (mean 5.8 ng ml-'), whereas, in controls, values ranged
from 1.7 ng ml' to 5.5 ng ml-' (mean of4.0 ng ml-') (P < 0.0001).
Plasma cytokine and receptor levels and other
prognostic variables
A linear correlation was observed between the plasma concentra-
tions of TNF, p55 and p75 (P < 0.0001 for each test), but not with
LTo. LToc plasma levels were not associated with any major prog-
nostic risk factor for HD and thus were not considered in the
further analysis.
Elevated plasma levels of TNF, p59 and p75 were significantly
associated with adverse prognostic factors at presentation, including
those related to the host (age over 60 years, poor performance status),
those related to the tumour (disease stage III/V, presence of bulky
tumour, extranodal disease involvement and increased serum levels
ofP2-microglobulin and LDH) and those related to the host-tumour
relationship (presence of B symptoms, low haemoglobin and serum
albumin levels) (Table 1). Elevated plasma levels of TNF were also
associated with hyperfibrinogenaemia (P < 0.005), higher serum
levels ofgammaglobulins (P < 0.05) and increased peripheral mono-
cytosis (P < 0.001), while elevated plasma levels ofp75 were associ-
ated with increased serum levels of alkaline phosphatase (P < 0.02).
Finally, TNF, p55 and p75 plasma levels were lower in nodular scle-
rosis than in the mixed cellularity histological subtype (P < 0.02,
P < 0.05 and P < 0.002 respectively).
Plasma cytokine and receptor levels and patient
outcome
To search for a possible prognostic significance of the TNF, p55
and p75 plasma levels, values greater than those observed in
Figure 1 Free-from-progression survival of HD patients according to risk
groups defined by the initial plasma levels of TNF, p55 and p75. The low-risk
group denotes that all three plasma markers were within their normal values
(n = 10), while the high-risk group denotes that the plasma levels of TNF, p55
and p75 were above these limits (n = 14). Patients with one or two plasma
markers elevated combined to form the intermediate-risk group (n = 37)
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Figure 2 Overall survival of HD patients according to risk groups defined by
the initial plasma levels of TNF, p55 and p75. The low-risk group denotes that
all three plasma markers were within their normal values (n = 10), while the
high-risk group denotes that the plasma levels of TNF, p55 and p75 were
above these limits (n = 14). Patients with one or two plasma markers
elevated combined to form the intermediate-risk group (n = 37)
healthy controls were established as cut-off points for discrimina-
tion of HD patients with elevated cytokine/receptor plasma levels
(14 pg ml-', 3.4 ng ml-' and 5.5 ng ml-' respectively). With this
criteria, we found elevated plasma levels of TNF in 48 (78%), of
p55 in 22 (35%) and ofp75 in 20 (32%) HD patients.
Among these 61 patients, 55 (90%) achieved a complete
response to treatment. Out of 61 patients, 12 (19%) patients have
experienced disease progression, while 49 (81%) have not, and
seven (11I%) patients have died. The median follow-up of the
patients remaining alive is 27 months. A complete response to
therapy was of a high predictive value for both FFP survival and
overall survival of HD patients included in the present analysis
(log-rank test P < 0.0001). Elevated plasma levels ofTNF, p55 and
p75 were markedly associated with a lower incidence ofcomplete
response to therapy (P < 0.01, P < 0.0005 and P < 0.0001 respec-
tively). Both p55 and p75 plasma levels, but not TNF plasma
levels, were also associated with shorter FFP survival and shorter
overall survival in univariate analysis (log-rank test P < 0.05).
Among the established prognostic factors for HD, only age over 60
years (but not over 45 years), advanced disease stage, poor perfor-
mance status, low serum albumin levels and extranodal disease
involvement (bone marrow and/or pleura) were found to influence
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Figure 3 Free-from-progression survival (left-panels) and overall survival (right panels) of HD patients according to the Straus (A and B), Hasenclever (C and
D), Proctor (E and F), Manchester (6 and H), Wagstaff (I and J) and TNF ligand receptor-based (K and L) indices. In each panel, the box denotes the number of
patients in each category defined by the index as published, and the P value denotes the result of the log-rank test
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both FFP and overall survival (log-rank test P <0.05). However,
the low number of events of disease progression and death did not
allow meaningful multivariate regression analysis for prognostic
variables in the present cohort of patients.
TNF ligand receptor-based prognostic factor model
As a predictive model that summarizes the relationship between
the elevated plasma levels of TNF, p55, p75 and outcome of HD,
we analysed them in combination rather than as individual plasma
markers because of the usefulness of the TNF-based prognostic
index in NHL patients (Warzocha et al, 1997). Three risk groups
were identified depending on the initial plasma levels of TNF, p55
and p75. The low-risk group denotes that all three plasma markers
were within their normal values (n = 10), while the high-risk group
denotes that the plasma levels of TNF, p55 and p75 were above
these limits (n = 14). Patients with one or two elevated plasma
markers combined to form the intermediate-risk group (n = 37).
The frequency of a complete response to treatment in the low-,
intermediate- and high-risk groups were, respectively, 100%, 92%
and 71% (P < 0.05). The actuarial 2-year FFP survival rates in
these groups were, respectively, 90%, 85% and 56% (log-rank test
P < 0.05) (Figure 1). Overall survival rates at 2 years in the low-,
intermediate- and high-risk groups were 100%, 93%, and 71%
respectively (log-rank test P < 0.01) (Figure 2).
Using our data set, we evaluated the importance of the TNF
ligand receptor-based prognostic index along with five other
reported prognostic indices for HD (Wagstaff et al, 1988; Straus et
al, 1990; Proctor et al, 1991; Hasenclever et al, 1995; Lee et al,
1997). The TNF ligand receptor-based prognostic index was the
only index to have a significant prognostic impact for FFP survival
(Figure 3K). Using the same indices for analysis of overall
survival, only the simplified Manchester index (low- and high-risk
groups) (Lee et al, 1997) and the index derived from the current
TNF, p55 and p75 plasma levels analysis were found to have
significant predictive values (Log-rank test P < 0.005 and
P < 0.01, respectively) (Figure 3H and L).
DISCUSSION
In this study, plasma levels of TNF, p55 and p75 were found to be
higher in HD patients than in healthy subjects, clearly suggesting
their increased production in the course of the disease. H-RS cells
have been reported to produce several cytokines and receptors,
including those of the TNF ligand receptor family members
(Nadali et al, 1994; Gruss and Dower, 1995). Therefore, the asso-
ciation between TNF and its soluble receptors' plasma levels and
disease extent and burden suggests the possibility that their plasma
levels in HD patients reflect the neoplastic component of the
disease. This suggestion is supported by the observations ofothers
who found elevated levels ofp55 TNF receptor and soluble CD30
in HD patients (Gruss et al, 1993; Nadali et al, 1994). In addition,
the TNF-related ligands may interact with surrounding reactive
cells, particularly T cells, which in turn may enhance the produc-
tion of cytokines and receptors in a paracrine fashion (Gruss and
Dower, 1995; Bazzoni and Beutler, 1996). The correlation
between TNF plasma levels and the number of monocytes
suggests that circulating reactive cells may also contribute to
enhanced TNF production in HD patients. Altogether, these data
indicate that both malignant and reactive cell populations may ulti-
mately influence TNF and its soluble receptor plasma levels in HD
patients. It is noteworthy that patients with the nodular sclerosis
histological subtype were found to have significantly lower levels
ofTNF and, to a lesser extent, ofp55 and p75 compared with those
with mixed cellularity histology. This observation indicates that a
possible heterogeneity of cytokine production in HD may be
linked to the histological features of the tumour.
The close associations between the elevation of TNF and its
soluble receptors in plasma and the presence of B symptoms,
hypergammaglobulinaemia, increased serum levels of fibrinogen
and alkaline phosphatase, anaemia and low serum albumin suggest
that the TNF ligand receptor system may be functionally involved
in the pathophysiological syndrome of inflammation and cachexia
associated with HD. Several studies have revealed possible ways
in which excessive TNF production could contribute to this
phenomenon (Tracey et al, 1988; Lindemann et al, 1989; Denz et
al, 1993; Gruss and Dower, 1995). Importantly, all these adverse
conditions may result in a poor performance status of the host and
may influence the patient's ability to tolerate therapy and, as a
consequence, result in a worse prognosis. Upon the stimulation
of TNF receptors, several transduction pathways are activated,
including the transcription factor nuclear factor kappa B (NF-KB),
which leads to the coordinated expression of many proteins
involved in further amplification of the inflammatory response.
Therefore, TNF is believed to play a pivotal role in persistent
immune activation (Bazzoni and Beutler, 1996; Barnes and Karin,
1997). Altogether, the plasma levels of circulating TNF and its
receptors seem to reflect several ongoing biological events
involved in the neoplastic process, including those related to the
tumour, the host and the tumour-host relationship.
Finally, our study indicates that the elevation of TNF and its
receptors constitutes an adverse prognostic parameter for HD
patients' outcome. Moreover, the combination of these parameters
in the prognostic index, already validated for NHL patients, was
found to be useful in identifying three categories ofHD patients with
different outcome. Interestingly, this index identified a subgroup of
patients, representing 16% of the entire population, in which no
death occurred, although no such subgroup was identified in our
population by any other published indices. This population should
therefore be considered for therapeutic attitudes that do not expose
HD patients to long-term therapy-related complications. On the
other hand, the TNF ligand receptor-based index allowed the identi-
fication of a quarter of the entire population of patients with a high
risk of progression or death, which occurred in about half of the
patients of this subgroup. The size of this high-risk group, which is
substantially larger than the high-risk groups identified in our popu-
lation by the Proctor or Manchester indices, allows the targeting ofa
category of patients in which more aggressive therapeutic attitudes
may be worth testing in the course of the disease. Thus, compared
with other indices already present for the selection of high-risk
patients, the TNF ligand receptor index seems promising both in
terms of the size ofthe subgroups with a particular prognosis and in
terms ofits statistical significance. It should be mentioned, however,
that some of these indices (Straus, Wagstaff and Manchester) were
developed for the identification of high-risk patients in advanced
HD patients, although the population analysed here was unselected.
In addition, because of the limited number of HD patients studied
here and of the relatively short follow-up, these results should be
considered as being preliminary; a largerprospective study is clearly
needed to confirm these encouraging results.
Further studies are also warranted as prognostic indices consist of
clinical and biological features that are mostly surrogate variables
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for the biological heterogeneity of the disease (Shipp, 1994). This
study and those presented by others (Gruss et al, 1993; Nadali et al,
1994; Seymour et al, 1997) clearly indicate the possible use of
certain biological markers along with established clinical and labo-
ratory variables for more appropriate prognostic risk assignment in
HD patients.
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